PPARα activation alleviates lithocholic acid-induced liver injury by inhibiting pyroptosis

Abstract

Background and aims: The mechanism of cholestatic liver injury (CLI) is unclear, and effective therapies are lacking. While peroxisome proliferator-activated receptor alpha (PPARα) agonists show potential hepatoprotective effect and pyroptosis is implicated in hepatocellular damage, how PPARα activation mitigates lithocholic acid (LCA)-induced pyroptosis remains unknown.

Methods: The hepatoprotective effect of PPARα agonists was evaluated in a mouse model of intrahepatic cholestasis induced by LCA. Liver injury was assessed via serum biochemistry, hematoxylin and eosin and TUNEL staining, and electron microscopy. Pyroptosis pathways were analyzed using real-time quantitative polymerase chain reaction, Western blot, and co-immunoprecipitation.

Results: Combined morphological, histopathological, and biochemical analyses confirmed that PPARα activation protects against CLI. Compared with LCA treatment alone, PPARα activation significantly attenuated the elevation of serum lactate dehydrogenase (LDH), the increased TUNEL-positive cells, and the formation of hepatocyte membrane pores. Mechanistically, PPARα activation suppressed both NOD-like receptor protein 3 (NLRP3) inflammasome-mediated pyroptosis and apoptosis protease-activating factor-1 (APAF-1)/CASPASE-3/GSDME-mediated pyroptosis. Furthermore, PPARα agonist pretreatment inhibited activation of the nuclear factor-kappa B (NF-κB) and forkhead box O1 (FOXO1) signaling pathways.

Conclusions: PPARα protects against LCA-induced CLI by inhibiting both NLRP3 inflammasome-mediated pyroptosis associated with NF-κB and APAF-1/CASPASE-3/GSDME-mediated pyroptosis associated with the FOXO1 signaling pathway.

Keywords

Cholestatic liver injury (CLI) / Peroxisome proliferator-activated receptor alpha (PPARα) / Pyroptosis / NOD-like receptor protein 3 (NLRP3) / Apoptosis protease-activating factor-1 (APAF-1)

References

[1] He G, Qing J . Bile acid—mediated interactions with various cell types in the cholestatic liver. DNA Cell Biol. 2025; 44:502-511. https://doi.org/10.1177/10445498251359370.

[2] Timor—Lopez E, Tolosa L, Donato MT . Cell—based approaches for the mechanistic understanding of drug—induced cholestatic liver injury. Arch Toxicol. 2025; 99:2243-2260. https://doi.org/10.1007/s00204—025—04016—0.

[3] Li HJ, Hao MY, Han HS, et al. Role of gasotransmitters in pyroptosis. Int J Biol Macromol. 2025; 322:146142. https://doi.org/10.1016/j.ijbiomac.2025.146142.

[4] Xu W, Che Y, Zhang Q, et al. Apaf—1 pyroptosome senses mitochondrial permeability transition. Cell Metab. 2021; 33:424-436 (e10). https://doi.org/10.1016/j.cmet.2020.11.018.

[5] Shen X, Zhang X, Li K, et al. Combined bacterial translocation and cholestasis aggravates liver injury by activation pyroptosis in obstructive jaundice. Heliyon. 2024; 10:e35793. https://doi.org/10.1016/j.heliyon.2024.e35793.

[6] Yang C, Jin X, Liu X, et al. TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Cell Death Dis. 2023; 14:47. https://doi.org/10.1038/s41419—023—05577—7.

[7] Han D, Kim H, Kim S, et al. Sestrin2 protects against cholestatic liver injury by inhibiting endoplasmic reticulum stress and NLRP3 inflammasome—mediated pyroptosis. Exp Mol Med. 2022; 54:239-251. https://doi.org/10.1038/s12276—022—00737—9.

[8] Ma X, Zhang W, Chen Y, et al. Paeoniflorin inhibited GSDMD to alleviate ANIT—induced cholestasis via pyroptosis signaling pathway. Phytomedicine. 2024; 134:156021. https://doi.org/10.1016/j.phymed.2024.156021.

[9] Liang HF, Yang X, Li HL, et al. Activation of pregnane X receptor protects against cholestatic liver injury by inhibiting hepatocyte pyroptosis. Acta Pharmacol Sin. 2025; 46:147-158. https://doi.org/10.1038/s41401—024—01357—x.

[10] Liang H, Yang X, Li H, et al. Schisandrol B protects against cholestatic liver injury by inhibiting pyroptosis through pregnane X receptor. Biochem Pharmacol. 2022; 204:115222. https://doi.org/10.1016/j.bcp.2022.115222.

[11] Hayes CM, Gallucci GM, Boyer JL, Assis DN, Ghonem NS . PPAR agonists for the treatment of cholestatic liver diseases: over a decade of clinical progress. Hepatol Commun. 2024; 9:e0612. https://doi.org/10.1097/HC9.0000000000000612.

[12] Lu Z, Li S, Luo J, et al. Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha—naphthylisothiocyanate. Pharmazie. 2021; 76:103-108. https://doi.org/10.1691/ph.2021.0988.

[13] Yang S, Wei L, Xia R, et al. Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPARα. Biochem Biophys Res Commun. 2019; 512:770-778. https://doi.org/10.1016/j.bbrc.2019.03.131.

[14] Shi Q, Xue C, Zeng Y, et al. PPARα agonist ameliorates cholestatic liver injury by regulating hepatic macrophage homeostasis. Int J Biol Macromol. 2025; 287:138510. https://doi.org/10.1016/j.ijbiomac.2024.138510.

[15] Dai M, Yang J, Xie M, et al. Inhibition of JNK signalling mediates PPARα—dependent protection against intrahepatic cholestasis by fenofibrate. Br J Pharmacol. 2017; 174:3000-3017. https://doi.org/10.1111/bph.13928.

[16] Ye X, Zhang T, Han H . PPARα: a potential therapeutic target of cholestasis. Front Pharmacol. 2022; 13:916866. https://doi.org/10.3389/fphar.2022.916866.

[17] Feng S, Tang J, Wei X, et al. Swertia cincta and its main active ingredients regulate the PPAR—α pathway in anti—cholestatic liver injury. J Ethnopharmacol. 2025; 337:118956. https://doi.org/10.1016/j.jep.2024.118956.

[18] Theys C, Vanderhaeghen T, Van Dijck E, et al. Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated steatotic liver disease (MASLD). Front Mol Med. 2024; 3:1283170. https://doi.org/10.3389/fmmed.2023.1283170.

[19] Jiao M, Wang J, Liu W, et al. VX—765 inhibits pyroptosis and reduces inflammation to prevent acute liver failure by upregulating PPARα expression. Ann Hepatol. 2023; 28:101082. https://doi.org/10.1016/j.aohep.2023.101082.

[20] Wang Y, Guan X, Gao CL, et al. Medioresinol as a novel PGC—1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα—GOT1 axis. Pharmacol Res. 2021; 169:105640. https://doi.org/10.1016/j.phrs.2021.105640.

[21] Li J, Dawson PA . Animal models to study bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2019; 1865:895-911. https://doi.org/10.1016/j.bbadis.2018.05.011.

[22] Shojaie L, Iorga A, Dara L . Cell death in liver diseases: a review. Int J Mol Sci. 2020; 21:9682. https://doi.org/10.3390/ijms21249682.

[23] Yu M, Zheng C, Li X, et al. Neutrophil extracellular traps—induced pyroptosis of liver sinusoidal endothelial cells exacerbates intrahepatic coagulation in cholestatic mice. Biochim Biophys Acta Mol Basis Dis. 2025; 1871:167700. https://doi.org/10.1016/j.bbadis.2025.167700.

[24] Padia R, Sun L, Liao YF, et al. HOXC8 impacts lung tumorigenesis by preventing pyroptotic cell death through the suppression of caspase—1 expression. Cell Death Dis. 2025; 16:552. https://doi.org/10.1038/s41419—025—07867—8.

[25] Yang S, Zou Y, Zhong C, Zhou Z, Peng X, Tang C . Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives. Front Cell Dev Biol. 2025; 13:1522206. https://doi.org/10.3389/fcell.2025.1522206.

[26] Zhou X, Shi Q, Li J, et al. Medicinal fungus Phellinus igniarius alleviates gout in vitro by modulating TLR4/NF—kB/NLRP3 signaling. Front Pharmacol. 2022; 13:1011406. https://doi.org/10.3389/fphar.2022.1011406.

[27] Kitamoto T, Watanabe H, Miyachi Y, et al. Concerted actions of FoxO1 and PPARα in hepatic gene expression and metabolic adaptation. Diabetes. 2025; 74:1748-1760. https://doi.org/10.2337/db24—1173.

[28] Adamowicz M, Kempinska—Podhorodecka A, Abramczyk J, Banales JM, Milkiewicz P, Milkiewicz M . Suppression of hepatic PPARα in primary biliary cholangitis is modulated by miR—155. Cells. 2022; 11:2880. https://doi.org/10.3390/cells11182880.

[29] Frissen M, Liao L, Schneider KM, et al. Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury. Hepatology. 2021; 73:1836-1854. https://doi.org/10.1002/hep.31494.

[30] Liao M, Liao J, Qu J, et al. Hepatic TNFRSF12A promotes bile acid—induced hepatocyte pyroptosis through NFκB/Caspase—1/GSDMD signaling in cholestasis. Cell Death Discov. 2023; 9:26. https://doi.org/10.1038/s41420—023—01326—z.

[31] Gallucci GM, Hayes CM, Boyer JL, Barbier O, Assis DN, Ghonem NS . PPAR—mediated bile acid glucuronidation: therapeutic targets for the treatment of cholestatic liver diseases. Cells. 2024; 13:1296. https://doi.org/10.3390/cells13151296.

[32] Cindoruk M, Kerem M, Karakan T, et al. Peroxisome proliferators—activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 2007; 7:44. https://doi.org/10.1186/1471—230X—7—44.

[33] Soret PA, Lam L, Carrat F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult—to—treat primary biliary cholangitis. Aliment Pharmacol Ther. 2021; 53:1138-1146. https://doi.org/10.1111/apt.16336.

[34] Hwang YP, Won SS, Jin SW, et al. WY—14643 regulates CYP1B1 expression through peroxisome proliferator—activated receptor α—mediated signaling in human breast cancer cells. Int J Mol Sci. 2019; 20:5928. https://doi.org/10.3390/ijms20235928.

[35] Yu M, Li X, Xu L, et al. Neutrophil extracellular traps induce intrahepatic thrombotic tendency and liver damage in cholestatic liver disease. Hepatol Commun. 2024; 8:e0513. https://doi.org/10.1097/HC9.0000000000000513.

[36] Batatinha HA, Lima EA, Teixeira AA, et al. Association between aerobic exercise and rosiglitazone avoided the NAFLD and liver inflammation exacerbated in PPAR—α knockout mice. J Cell Physiol. 2017; 232:1008-1019. https://doi.org/10.1002/jcp.25440.

[37] Wang J, Sun Z, Xie J, et al. Inflammasome and pyroptosis in autoimmune liver diseases. Front Immunol. 2023; 14:1150879. https://doi.org/10.3389/fimmu.2023.1150879.

[38] Ikenaga N, Liu SB, Sverdlov DY, et al. A new Mdr2(—/—) mouse model of sclerosing cholangitis with rapid fibrosis progression, early—onset portal hypertension, and liver cancer. Am J Pathol. 2015; 185:325-334. https://doi.org/10.1016/j.ajpath.2014.10.013.

[39] Wang L, Cao ZM, Zhang LL, Li JM, Lv WL . The role of gut microbiota in some liver diseases: from an immunological perspective. Front Immunol. 2022; 13:923599. https://doi.org/10.3389/fimmu.2022.923599.

[40] Awoniyi M, Wang J, Ngo B, et al. Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC. Gut. 2023; 72:671-685. https://doi.org/10.1136/gutjnl—2021—326500.

[41] Wen W, Wang J, Zhang B, Wang J . PPARα agonist WY—14643 relieves neuropathic pain through SIRT1—mediated deacetylation of NF—κB. PPAR Res. 2020; 2020:6661642. https://doi.org/10.1155/2020/6661642.

[42] Wang R, Zhao J, Jin J, et al. WY—14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC. Lipids Health Dis. 2022; 21:121. https://doi.org/10.1186/s12944—022—01726—7.

[43] Zhao W, Ma L, Cai C, Gong X . Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF—κB and A2aR signaling in LPS—induced THP—1 macrophages. Int J Biol Sci. 2019; 15:1571-1581. https://doi.org/10.7150/ijbs.34211.

[44] Li W, Sun J, Zhou X, Lu Y, Cui W, Miao L . Mini—review: GSDME—mediated pyroptosis in diabetic nephropathy. Front Pharmacol. 2021; 12:780790. https://doi.org/10.3389/fphar.2021.780790.

[45] Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins JR . FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. Cancer Res. 2013; 73:6056-6067. https://doi.org/10.1158/0008—5472.CAN—13—0453.

[46] Zhang Y, Yang J, Fan S, et al. The reversal of PXR or PPARα activation—induced hepatomegaly. Toxicol Lett. 2024; 397:79-88. https://doi.org/10.1016/j.toxlet.2024.05.006.